Diagnostic Performance of CIM for Helicobacter Pylori Infection in Patients With Peptic Ulcer Bleeding

Launched by MAHIDOL UNIVERSITY · Feb 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new method called the Current Infection Marker (CIM) to detect a bacteria known as Helicobacter pylori (H. pylori) in patients who have serious stomach bleeding caused by peptic ulcers. The researchers want to find out how well the CIM method works compared to other tests like the rapid urease test, biopsies, and breath tests. They will look at things like how accurate the tests are and how often they give correct or incorrect results. The goal is to see if CIM is a better option for detecting this infection in patients who are experiencing upper gastrointestinal bleeding.

To participate in this trial, you need to be at least 18 years old and have experienced upper gastrointestinal bleeding, with a diagnosis of a peptic ulcer confirmed through an endoscopy (a test where a doctor looks inside your stomach). However, if you have certain health issues, like unstable blood pressure or previous stomach surgery, you may not be eligible. If you join the study, you will undergo tests that help doctors understand the best way to detect H. pylori and improve treatment for patients with similar conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Upper gastrointestinal hemorrhage and undergo esophagogastroduodenoscopy with diagnosis of peptic ulcer
• Exclusion Criteria:
• • Inappropriate gastric mucosal biopsy conditions such as hemodynamic instability, coagulopathy or severe thrombocytopenia or massive bloody content in gastric cavity or duodenum
• • Previous history of gastric surgery such as partial or total gastrectomy